Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the IDEAYA management team. We've got Yujiro Hata, the CEO, and Josh Bleharski, the CFO. Thanks so much for joining us today.
Thank you so much, Maury, and look forward to the discussion today.
We'll do fireside chat format. So maybe for those who are new to the story, if you can give a one-minute intro to the company.
IDEAYA Biosciences, we're a leading precision medicine oncology company. Our lead program, darovasertib, recently had positive top-line results, which we presented at an oral presentation at ASCO. We did recently announce that at the end of the third quarter, we did complete the NDA submission. So we do anticipate having NDA acceptance on that here relatively soon. As you know, Maury, most of our analysts are projecting a first half of next year commercial launch in the metastatic uveal melanoma setting. In addition, we have a phase III adjuvant study that's now well underway. In addition, we have a very broad portfolio on DLL3-TOPO ADC. We did have an announcement this morning of our plans to also advance not just in small cell lung cancer, but also neuroendocrine carcinoma into a phase III study, as well as a potential single-arm design in GEP-NEC for potential accelerated approval.
Beyond that, Maury, you were there at our R&D Day yesterday. We had a lot of key updates across the MTAP and CDKN2A pipeline. I would say big focus here is what we believe is a potential first-in-class molecule for PRMT5. We showed some early safety data, some pharmacodynamic data, as well as what we believe is a very clean drug-drug interaction profile to enable combinations with molecules such as pan-RAS and KRAS G12D. Also, we did profile a new molecule, CDKN2A, that we are targeting to have in the clinic in the first half of next year. This is targeting a biomarker setting of CDKN2A deficiency, which we believe represents a very large percentage of pancreatic cancer, approximately 70%. Lastly is around KAT6/7, our first-in-class dual inhibitor. Here, a significant focus on breast cancer.
Also here, we showed some early safety data, some pharmacodynamic data, as well as an early response in a fifth-line breast cancer patient. So, a lot of activities and obviously a lot of upcoming catalysts in 2027 as well.
Yeah. I think that's a great intro. You have the upcoming commercial launch and approval, and then so much happening in the pipeline. So maybe let's dive into darovasertib first. You completed the NDA submission in third quarter under RTOR with Fast Track designation in place. How are you setting expectations for timing of the NDA acceptance announcement, and how should we think about the review timeline heading into 2027?
Yeah. So we have a lot of different designations for this agent, including Fast Track, breakthrough, RTOR, orphan drug. The timing with the NDA submission at the end of the third quarter, we do think the NDA acceptance timing is here very soon. We have not provided specificity on that, Maury, but it will be anticipated this quarter. Then in terms of the review cycle or the review time period, because we have Fast Track designation as well as under RTOR, we do believe we will have an expedited review. So we have not specified exactly when. We anticipate we will likely do that once we have more visibility into the actual PDUFA date.
Got it. Okay. You described a positive trend in early OS with just over 10 months at ASCO from your dataset. How much extra follow-up is in the NDA, what proportion of OS events are in the filing? If the OS trend is positive, has FDA indicated to date whether they would be willing to include those data in the label?
Yeah. The interim analysis for OS is projected for first half, sorry, middle of next year. We do anticipate it is going to still be early as it relates to the OS events. In terms of the question of how much more follow-up, there is roughly about six months more follow-up since what we provided at the top-line results. In terms of how many events that would represent from a percentage basis, I do not think we are prepared to make comments on that at this point yet. Would it be able to be incorporated into that approval? I think some of it will just depend on where we are on the events. As I mentioned earlier, I think we do think it is going to be likely early at this point.
Got it. Okay. There is debate on the HLA-positive population. At ESMO, you presented ORR and durability data from 11 treatment-naive and 75 previously treated HLA-positive patients with a March cutoff. The recent publication included a similarly sized frontline HLA-positive cohort with less follow-up. What gives you confidence that the dataset that you have is going to be sufficient for inclusion in the label or NCCN listing?
Yeah. First, what we would start with is based on the mechanism of action. We know that our molecule is directly focused on the activating mutation of GNAQ/11, which is the predominance of this population, and that mechanism of action is not specifically linked to HLA-A2 status. I think that is really the first place to start. Second is the data that we presented at ESMO, roughly 100 patients in the HLA-A2 positive setting. Our perspective is the molecule is clearly active in that setting. That is the mindset by which we went through the process and filing the NDA. We also appreciate on this specific point, this will be ultimately a review issue with the FDA.
This study was done in the HLA-A2 negative setting, but for all the reasons we noted, we are pursuing a broader approach, because we believe this therapy should be active across all metastatic uveal melanoma patients. Beyond that, either way, we will be also pursuing an NCCN strategy to be able to hopefully have this treatment available to patients more broadly.
Got it. Based on the events, and going back to OS, based on the events that you are seeing, sounds like you are pretty confident it is going to be middle of next year. Could that get bumped to second half? I guess, early next year, could you provide more granularity on timing around it?
Yeah. We are going to have an assessment as part of the NDA submission. Again, it is not going to be a formal analysis because the interim, as noted, is middle of next year. Might we give some communication on that early next year? It is possible, but if we do not, I would not look into that either way. But yeah, at this point, we do not have a reprojection on that interim analysis from what we had noted earlier.
Got it. Okay. You plan to submit the phase II neoadjuvant data for guideline inclusion. You plan to submit it to NCCN post-approval around the same time as the HLA-positive data, and would this be part of an ad hoc review outside of the usual annual cycle? How confident are you that NCCN would do that ad hoc review?
Sure. Yeah. That's right, Maury. I think what would happen is, upon an approval in the metastatic setting, we would submit the published data to the panel for review and inclusion in the compendia listing. It's really hard to know with any certainty whether it gets included or not, but I would say that there's really nothing for these patients, and the consistency and quality of the data that we've shown thus far for both the enucleation-eligible as well as the plaque-eligible patients gives us confidence that it would get included in at least one of those subsets, if not both. The timing of a committee or a panel, we would hope it would be ad hoc just in light of the unmet medical need in this indication. But again, that would have to be something we'd see.
Okay. Got it. You dosed the first patient in your pivotal adjuvant study with Servier in September, with patients randomized within 120 days of completing primary local therapy. Given that staggered site activation and screen failure rate slowed neoadjuvant enrollment, how are you thinking about efficient patient identification and site activation pace for the adjuvant study?
Yeah. So far, everything is going as planned. Maury, as you noted, because of the experience we had on the neoadjuvant trial, this is definitely an area that we're very focused on, that enrollment is staying on track. I think so far what we can say is enrollment is on track and currently stays in pace with our internal projections, which is great news. We do anticipate fast uptake in this trial, mainly because this is, again, an area of very high unmet need. We know there's a lot of interest in this study in terms of adjuvant and obviously the primary endpoint being around relapse-free survival. So, we do feel confident about our ability to enroll this study quite rapidly.
Got it. For how long it would take to enroll this study, any more perspective on the timeline there?
Yeah. We haven't given that specific visibility. I would say as we get further into the enrollment, anticipate that we will do that, perhaps sometime next year.
Got it. Okay. Let's talk about IDE849, your DLL3 ADC asset. You are going to share your first global phase I/II data update by the end of this year, early next year. Talk about what we should expect for that update. How many efficacy-evaluable patients, and what is the small cell versus NEC and the second line versus later line mix they are going to have, and how much follow-up?
Yeah. We do hope to have a meaningful dataset in terms of patient numbers. It will likely be north of 30 patients. I think we are still evaluating that. I think that is going to be likely mainly driven by how much follow-up we have for these patients. We anticipate it will likely be split largely 50/50 between small cell lung cancer and NEC. We will have, we think, GEP-NEC, LC-NEC on the NEC side. For small cell lung cancer, we will have a decent dataset, we think, in the post-IMDELLTRA setting, which will be important. As you know, Maury, that has been the focus of our phase III study design.
Right. How many patients would you have in the post-IMDELLTRA?
Yeah. I think that's still a TBD. I think for now what we'll say is ideally over 30 patients, and hopefully we'll be able to give more color on that in terms of how many post-IMDELLTRA. But I think we'll have a meaningful enough dataset to be able to establish that we are indeed seeing activity in the post-IMDELLTRA setting. I know this question has come up before, which is post a DLL3 T-cell engager, will we have the ability to deliver responses with another DLL3 modality? Our view is absolutely yes. I think we'll be able to have enough data to answer that question very firmly.
Got it. For response rate in that particular population, what's your goal there? Do you think it would be similar to Hengrui's approximate 55%?
Yeah. We think the response rate, really guidance here, it's going to be less about is it post-IMDELLTRA, but will be more about what line of therapy. As you may recall, Maury, in the second line setting, we reported a confirmed response rate about 60%. In that third line setting, it was more in the about 50% range. Our view is as long as we can deliver a consistent response rate based on line of therapy, whether it's pre or post-IMDELLTRA, that's the objective.
Got it. Okay. You had the press release this morning. Maybe talk about immediate next steps for the program.
Yeah. We're quite excited about the NEC set of indications, and there are several reasons for that. First is we believe this is an area of very high unmet need. It's not as crowded in terms of antibody-drug conjugate activity. We think there's a significant opportunity for IDE849. Second, we've seen clear efficacy across several NEC subtypes, including GEP-NEC and LC-NEC. We do think the probability of success for a registrational trial should be quite high. Considering we know in the refractory setting of NEC, the standard of care is chemotherapy. Response rates are likely in the teens, maybe low teen percent range, where we reported a response rate of roughly 50%. Under any lower bound calculation, I think we're going to be in a really good position.
Also importantly, we noted two studies that we're anticipating moving forward with, which I think positions us very competitively relative to our peers, which is first is our randomized controlled phase III study. In the refractory NEC setting, this will be multiple NEC subtypes. That would be our effort to get multiple indications within NEC. Then a single-arm phase II component with a focus specifically on GEP-NEC, roughly 90 patients to get us hopefully even faster approval for that specific indication. So that's the current strategy, and we look forward to getting those studies launched by year end.
Got it. For small cell, maybe talk about the plan there and what timelines could look like to start a phase III there.
Yeah. I would say the most important piece to be aware of for small cell lung cancer is some of the recent data that we saw at ESMO with IMDELLTRA, specifically in frontline maintenance. We know based on that data that that landscape has really transformed. So what we're doing in the small cell lung cancer area is really informed by a lot of the different data sets that have been coming in small cell lung cancer. First, Maury, as you know, the later line approval on small cell lung cancer will be a randomized study. But importantly, what we think why we're differentiated and why we believe we have the best clinical trial design strategy is that we are doing it in the post-IMDELLTRA setting.
That will put us, we think, in a significant, a really good spot, mainly, A, because IMDELLTRA is now moving into frontline maintenance. So by default, this becomes a second-line opportunity for us, and it is also a very clean data set versus doing a pre and post-IMDELLTRA population, which we believe will be more of a heterogeneous population. So we believe our study design is consistent with the discussions we had with the FDA on what a registrational study would look like in that later line setting. For frontline, we think with the IMDELLTRA data that the frontline maintenance landscape has transformed, which is great for patients. So our view for frontline is that the focus should be in the induction setting, and ideally with a differentiated combination.
There are several approaches that we are interested in, and there are different conversations ongoing, but I would say a key focus is considering a T-cell engager as a potential anchor to consider a differentiated combination in frontline.
Got it. Makes sense. You had the R&D Day yesterday, so I want to dig into some of the takeaways from that. Maybe just starting off, if you can highlight three key takes from your perspective.
Yeah. First and foremost, I would say message one is we do believe we have a potential best-in-class PRMT5 inhibitor. We have demonstrated our ability to deliver appropriate exposures where we are well exceeding the target EC90 coverage that we know that you should be able to deliver a partial response level type of activity. We also know at those exposure levels, we are seeing a very good safety profile. As you know, we showed a Grade 3 or higher AE rate in the single-digit percent range. We are not seeing certain AEs such as skin rash that have been observed by other PRMT5 inhibitors. We have also not seen CNS-related tox, which as you know, have been observed by other PRMT5 inhibitors. We are also seeing very minimal GI-related AEs relative to other data sets we have seen before.
Second, I would say we think very critical because we think one of the core strategies for PRMT5 will be how to utilize it as an effective combination agent, and that's where safety will be paramount. Second, ideally, you have a very clean drug-drug interaction profile. We clearly, we believe we do, both from a preclinical perspective and based on also early clinical data we showed already that we don't observe drug-drug interaction with another CYP3A4 molecule. So that's, I would say, takeaway one. Second is KAT6/7, also another clinical stage compound which we shared early data. We are also seeing response level activity for that agent. We appear to be seeing an early safety profile that looks favorable relative to a KAT6 selective inhibitor, which was an important question we wanted to answer.
Here, I think similar to some other activities that have been done here, we think can be a very compelling combination with pan-RAS, specifically to address this interplay between the MAP kinase pathway, which RAS is involved in, with the Wnt/Myc pathway, which we think creates a therapeutic opportunity for KAT6, in particular as a combination in indications such as KRAS CRC. The last piece, which is we think an emerging program that we think will continue to differentiate us in the MTAP/CDKN2A and RAS field, and that's based on our new development candidate that we announced, IDE101, a critical target going after CDKN2A deficiency, which is prevalent in roughly 70% of pancreatic cancer.
Here, you can imagine a doublet with a pan-RAS and PDAC, potentially in an unselected patient population, and also a doublet with PRMT5, because we know that both MTAP and CDKN2A are located on the 9p21 chromosome. They're about 2,000 base pairs apart, so this would be a plug-and-play combination across essentially any solid tumor indication of MTAP. That is now projected to be in the clinic first half of next year.
Got it. Yeah, it was covered a lot there. Maybe let's dig into PRMT5 first. I had a question on the combo with MAT2A. The expansion there, timelines have shifted a bit to first half of next year. Just what drove the change in timing? Was it something with dose optimization or combo safety? What response rate and tolerability profile would justify advancing that?
Look, we continue to be highly committed to the combination between PRMT5 and MAT2A. Here, the indication focus will be lung cancer. Here, in terms of that shift, a timeline, Maury, this has really been about just the dose escalation and dose optimization. We do believe we are now starting to enter that clinically efficacious dose range for that combination. And really, our hope for objective here is, can we deliver greater durability? If we can do that, then we think there will be clearly a path forward for us, and we will be very differentiated amongst our peers. Here, in terms of what is a target threshold of what good looks like, I think ideally you are seeing a combination response rate that is ideally 40% or higher in lung cancer.
But as you know, some of it will depend on what line that you are in, whether those are second-line patients, third-line patients, or later-line patients.
Yeah. So, I guess 40% or higher, which line would you want to focus on then?
I think there probably is just in the second-line area. I think once you are going third line plus, I think that threshold is probably lower.
Got it. Okay. For PDAC, the PRMT5 combo with Roche's pan-RAS combo is targeted to start by year end. Genentech is going to run the G12D combo. Given daraxonrasib is becoming the standard of care and Tango's further along and has a unique DDI profile, how are you thinking about differentiation and positioning?
Yeah. First, we will start with our view in PDAC, frontline PDAC, especially focusing on the MTAP deletion population. That area is completely wide open still, and we are very much right in that race. We do anticipate we should be hopefully dosing our first patient with the Roche pan-RAS by the end of the year. That continues to be the objective. We would anticipate that that initial combination cohort should be at an active dose. So it should be a fairly truncated dose escalation, and we could rapidly build a meaningful data set fairly rapidly and quickly. We would hope, assuming that data set is positive, hopefully we are in a position to start thinking about what a registrational study may look like towards the end of next year, which from a timing perspective, I think, again, that positions us very well.
G12D is probably about a quarter staggered from that timeframe. Again, here, I think a lot of different activities that are ongoing from various companies. We feel very good about the Roche molecules and our collaboration with them thus far. I would say the clinical strategy is very aligned between the two organizations as well. We appreciate daraxonrasib is approved, also standard of care. So we are evaluating the ability to potentially create some early clinical proof of concept with that molecule. That is something that those discussions are still ongoing internally as well.
Got it. Maybe just talk briefly on why you picked the Roche pan-RAS.
I would say that partly it was driven by the quality of their molecules. Second is around, I would say, alignment about how we view the opportunity in pancreatic cancer. Obviously, we have seen the remarkable results that daraxonrasib has delivered in the refractory PDAC setting, but with a view that we can do better through novel combinations with an eye towards getting in the frontline setting. I think all of those themes were aligned between the organizations.
For IDE892 plus pan-RAS, when could you have data from that, and what would you want to show?
We would hope that we would be in a position to share data next year on that. Here, I think, ideally, it is a clinical proof of concept data set, 20 patients, 30+ patients at a relevant dose. I think in particular, answer several critical questions. Of course, efficacy, basic safety, as well as, we think very importantly, that we do not observe a drug-drug interaction. For all the reasons we mentioned, we do not believe that is going to be the case. Obviously, we would like to be able to share that data as well.
Got it. Maybe briefly on the KAT6/7, you showed the safety data there as well in PD data. Why do you see better safety with targeting KAT6/7 versus KAT6 alone, especially on anemia? For your data update in 2027, what could you show for that update?
Yeah, I think there's probably two parts to note here. First, on KAT6, if you look at a lot of the molecules that were advanced in the clinic in KAT6, most of them were off of the same scaffold that Pfizer had. I would say they're chemically more similar than different, at least from our perspective. I think there are some questions of how much of it may have been directly target-specific versus chemical scaffold-specific. Our chemistry is quite unique and different from that. That's the first part. Second, and I think, Maury, we had talked about this even before the molecule went into the clinic, because we believe hitting both six and seven really brings on new biology that can drive greater efficacy, the question is also how hard do we actually have to hit six to deliver the efficacy result we want to observe?
And so there could be a scenario that might we see greater safety because the balance of what we need to do from how hard we're hitting these targets is just a different paradigm. So far, at the end, it's all going to be based on the data we generate in the clinic. But thus far, as you've seen, both related to dysgeusia, dramatically lower than what we're seeing so far from what KAT6 has reported. Also in terms of myelosuppression rates, we're multiples lower right now, as you know from what we've reported. So I think we've got an attractive molecule. Now, for us, really the significant objective will be what kind of monotherapy response rate can we deliver with this agent, particularly in indications like breast cancers? Because as we know, for KAT6 alone, the monotherapy response rate we saw was only about 10%.
If we can take that to a much higher level, we think that could be quite transformative for breast cancer and potentially other indications like CRC.
And maybe one question on CDKN2A. What do you want to see with monotherapy to justify the combination with the pan-RAS?
Based on the preclinical data, we do anticipate we will be able to deliver monotherapy activity, particularly in the CDKN2A deficiency setting. Here, we will evaluate pancreatic cancer, potentially other indications. But one of the main reasons we did bring this into the clinic was with the mindset to enable combinations to competitively position ourselves in the KRAS and MTAP area, as we discussed in the beginning. That is the central focus for the program, but we do anticipate we are going to see fairly robust monotherapy activity. I would hope, if not comparable to PRMT5, more than what we have observed with PRMT5.
Got it. Okay. We are out of time, so maybe just in closing, if you want to highlight cash and key catalysts ahead over the next 6-12 months.
Sure. Josh.
Yeah. We ended the last quarter with about $1.1 billion in cash on the balance sheet. Our runway guidance has remained the same, giving us cash into 2030. I think we talked about a lot of the catalysts here, obviously, the NDA preparation, acceptance, launch preparation for the first half of next year, datasets from DLL3, our own global trial, as well as updates across the PRMT5 and RAS combination and other MAT2A portfolio.
Got it. Yujiro, Josh, thanks so much for joining us today.
Yep. Thank you, Maury.